-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on AtriCure, Lowers Price Target to $50

Benzinga·07/28/2026 19:34:46
Listen to the news
UBS analyst Priya Sachdeva maintains AtriCure (NASDAQ:ATRC) with a Buy and lowers the price target from $55 to $50.